| Species |
Human |
| Protein Construction |
| His |
CDH16/Cadherin 16 (Lys19-Ala786)
Accession # O75309-1 |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized CDH16/Cadherin 16, His, Human at 0.5μg/ml (100μl/well) on the plate can bind AntiCDH16 Antibody, Mouse IgG Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
84.37 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 90-110 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22 μm filtered solution in 50mM Tris, 100mM NaCl (pH 8.0). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Cadherin (CDH)16/kidney-specific-cadherin was first described as a kidney-specific adhesion molecule and thereafter found expressed also in the thyroid gland. CDH16 is a thyroid-selective and hormone-dependent adhesion protein that might play a role during thyroid development and that may be a useful marker to monitor thyroid carcinomas. |
| Synonyms |
Cadherin-16; CDH16; Ksp-cadherin |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
